Danaher Corporation (DHR) outlined a growth strategy under new CEO Julie Brown, targeting higher sustainable core growth and expanded market share in life sciences and diagnostics. The company expects 4% to 5% core growth next year, excluding respiratory in China, supported by bioprocessing and diagnostics.

Brown identified four priorities: commercial excellence, innovation, talent and capital allocation. Danaher is deploying its Business System to improve funnel management, account planning and cross-company selling. The company spends roughly $1.7 billion annually on innovation and plans to hold that level steady while improving return on investment. Diagnostics innovation efforts have lifted forecasted growth by 80% after the company focused on key priorities.

The diagnostics platform demonstrates the strategy's potential. Revenue grew from $6 billion in 2017 to $11 billion today, while operating profit tripled. Leica Biosystems accelerated from mid-single-digit growth to high single-digit growth through tighter commercial execution and funnel management.

Danaher deployed more than $11 billion in acquisitions this year, including Masimo and StatLab, both expected to deliver strong high-single-digit returns on invested capital by year five or earlier. Masimo posted high-single-digit volume growth in its first full quarter with Danaher. The company has completed more than 10 kaizens at Masimo to improve lean conversion and margins.

Cytiva remains a high single-digit growth business long-term, supported by monoclonal antibodies, biosimilars and advanced modalities. Brown quantified a $1 billion reshoring opportunity by 2028 and beyond, with early brownfield orders already coming through.

Danaher leverages its broad portfolio in artificial intelligence drug discovery, with offerings spanning instrumentation, automation, consumables and software. An autonomous laboratory model for affinity reagents showed an 8x productivity benefit. The company partnered with NVIDIA to make instruments smarter and with Anthropic on digital twins experimentation.

Investors monitoring DHR should watch for execution on the 4% to 5% core growth target and return on the $1.7 billion annual innovation spend.